Market Indices
Sector Heatmap
CCCC — C4 Therapeutics, Inc.
NasdaqC4 Therapeutics, Inc.
- O
- 3.19
- H
- 3.33
- L
- 2.93
- V
- 3.37M
CCCC — Latest News & Headlines
10 StoriesC4 Therapeutics (Nasdaq:CCCC) - Stock Analysis - Simply Wall Street
C4 Therapeutics (Nasdaq:CCCC) - Stock Analysis Simply Wall Street
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? Yahoo Finance
In two patients with blood cancer, tests suggest a drug combo may keep immune cells from wearing out. - Stock Titan
In two patients with blood cancer, tests suggest a drug combo may keep immune cells from wearing out. Stock Titan
C4 Therapeutics Reports Phase 1 Cemsidomide Biomarker Data Showing T-Cell Activation and Advances Elranatamab Combination Trial - Quiver Quantitative
C4 Therapeutics Reports Phase 1 Cemsidomide Biomarker Data Showing T-Cell Activation and Advances Elranatamab Combination Trial Quiver Quantitative
Director receives 4,618 shares instead of cash compensation at C4 Therapeutics (CCCC) - Stock Titan
Director receives 4,618 shares instead of cash compensation at C4 Therapeutics (CCCC) Stock Titan
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026 - Seeking Alpha
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026 Seeking Alpha
C4 Therapeutics Director Donna Roy Grogan Receives 4,618 Shares Instead of Cash Compensation - Kalkine Media
C4 Therapeutics Director Donna Roy Grogan Receives 4,618 Shares Instead of Cash Compensation Kalkine Media
Shares replace cash pay as C4 Therapeutics (CCCC) director receives 3,662 shares. - Stock Titan
Shares replace cash pay as C4 Therapeutics (CCCC) director receives 3,662 shares. Stock Titan
C4 Therapeutics (NASDAQ: CCCC) CFO logs RSU shares, withholds stock for taxes - Stock Titan
C4 Therapeutics (NASDAQ: CCCC) CFO logs RSU shares, withholds stock for taxes Stock Titan
C4 Therapeutics: 53% of 20 respond at trial dose - Stock Titan
C4 Therapeutics: 53% of 20 respond at trial dose Stock Titan